Novartis told to pay $178m over infringing cancer drug
26-07-2021
360b / Shutterstock.com
The US Food and Drug Administration (FDA) has recommended that an application by pharmaceutical company Novartis to market a biosimilar version of Amgen’s cancer drug Neupogen (filgrastim) be approved.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Novartis, Sandoz, biosimilars, FDA, Amgen, Neupogen
